[
  {
    "ts": "2025-07-29T21:25:02+00:00",
    "headline": "Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates",
    "summary": "Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/cardiff-oncology-crdf-reports-q2-212502550.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d5debfb6-550e-3360-8888-89feafeb82b6",
      "content": {
        "id": "d5debfb6-550e-3360-8888-89feafeb82b6",
        "contentType": "STORY",
        "title": "Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates",
        "description": "",
        "summary": "Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2025-07-29T21:25:02Z",
        "displayTime": "2025-07-29T21:25:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0sIIP41M0Yl73BbPadjNMg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WsNU52Eg.hsicG83rNZXgw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cardiff-oncology-crdf-reports-q2-212502550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cardiff-oncology-crdf-reports-q2-212502550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRDF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-29T13:15:03+00:00",
    "headline": "Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
    "url": "https://finance.yahoo.com/news/unlocking-q2-potential-regeneron-regn-131503310.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "99fdce8f-799d-31dd-85c1-327f2dcfb4ff",
      "content": {
        "id": "99fdce8f-799d-31dd-85c1-327f2dcfb4ff",
        "contentType": "STORY",
        "title": "Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics",
        "description": "",
        "summary": "Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.",
        "pubDate": "2025-07-29T13:15:03Z",
        "displayTime": "2025-07-29T13:15:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
          "originalWidth": 1000,
          "originalHeight": 603,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YgRrCYuBdR1wa08RtjoPHQ--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9.cf.webp",
              "width": 1000,
              "height": 603,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jAWLk_UfDMDSToA2irhEEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/unlocking-q2-potential-regeneron-regn-131503310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/unlocking-q2-potential-regeneron-regn-131503310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]